AbbVie recently announced encouraging results from the SURVEYOR clinical trials of its investigational HCV drug regimen, ABT-493 and ABT-530, in non-cirrhotic patients who are positive for chronic hepatitis C virus (HCV) infection. Specifically, ABT-493, an inhibitor of the NS3/4A protease, ... Read more